SavedAdd your journal

Journals / Türk Nöroloji Dergisi / 2018 / Cilt: 24 - Sayı: 1

Intravenous Thrombolytic Therapy in Acute Stroke: Frequent Systemic Problems and Solutions

Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri

Dilek ÖRKEN NECİOĞLU
Erdem GÜRKAŞ
Atilla Özcan ÖZDEMİR
Şerefnur ÖZTÜRK
Mehmet Akif TOPÇUOĞLU
Ethem Murat ARSAVA
Pages
13–25
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, questions about systemic nonneurologic conditions, problems related with IV tPA treatment and complications of treatment, which were collected from our colleagues practicing in Turkey and which are more important in clinical practice, were answered on the basis of the current literature and clear recommendations are made

📌 3 Key Takeaways

🎯
Objective & Hypothesis:One of the most important reasons why the use of the intravenous (IV) tissue plasminogen activator (tPA), which is one of the key elements of acute ischemic stroke treatment, is not sufficiently widespread is the fact that many common questions have not been adequately answered.
📊
Key Findings & Data:One of the most important reasons why the use of the intravenous (IV) tissue plasminogen activator (tPA), which is one of the key elements of acute ischemic stroke treatment, is not sufficiently widespread is the fact that many common questions have not been adequately answered.
💡
Conclusion & Impact:In this review, questions about systemic nonneurologic conditions, problems related with IV tPA treatment and complications of treatment, which were collected from our colleagues practicing in Turkey and which are more important in clinical practice, were answered on the basis of the current literature and clear recommendations are made
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

One of the most important reasons why the use of the intravenous (IV) tissue plasminogen activator (tPA), which is one of the key elements of acute ischemic stroke treatment, is not sufficiently widespread is the fact that many common questions have not been adequately answered. In this review, questions about systemic nonneurologic conditions, problems related with IV tPA treatment and complications of treatment, which were collected from our colleagues practicing in Turkey and which are more important in clinical practice, were answered on the basis of the current literature and clear recommendations are made

Özet

Akut iskemik inme tedavisinin ana elementlerinin başında gelen intravenöz (IV) doku plazminojen aktivatörü (tPA) kullanımının yeterince yaygınlaşamamasının en önemli nedenlerinden biri sık karşılaşılan birçok soruya yeterince yanıt veril(e)memiş olmasıdır. Bu derlemede akut inmede IV tPA tedavisi ile ilgili olarak meslektaşlarımızdan toplanan, daha çok uygulamada önemi olan sistemik soru ve sorunlar ile tedavinin komplikasyonlarına dair, sorulara güncel literatür temelinde yanıt verilmiş ve net tavsiyelerde bulunulmuştur

🔖

Cite This Article

NECİOĞLU, D. Ö., GÜRKAŞ, E., ÖZDEMİR, A. Ö., ÖZTÜRK, Ş., TOPÇUOĞLU, M. A., ARSAVA, E. M. (2022). Intravenous Thrombolytic Therapy in Acute Stroke: Frequent Systemic Problems and Solutions. Türk Nöroloji Dergisi, Cilt: 24 - Sayı: 1, 13–25. https://ajindex.com/articles/636745

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016;47:581-641
  2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587
  3. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947
  4. TCSB. ACTILYSE 50 mg 1 flakon Kullanma Talimatı PDF Dosyası. Ulaşılan web sitesi: http://wwwilacrehbericom/pdfs/actilyse-50-mg-1-flakon-870d/ kt/ 2012; Ulaşım tarihi: 21/4/2017(Boehringer Ingelheim İlaç Tic. A.Ş. Güncelleme: 7 September 2012)
  5. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329
  6. Bhatnagar P, Sinha D, Parker RA, Guyler P, O'Brien A. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and metaanalysis to aid decision making in patients over 80 years of age. J Neurol Neurosurg Psychiatry 2011;82:712-717
  7. Asuzu D, Nystrom K, Amin H, Schindler J, Wira C, Greer D, Chi NF, Halliday J, Sheth KN. Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis. Neurocrit Care 2015;22:229-233
  8. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR; VISTA Collaborators. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010;41:2840-2848
  9. IST-3 collaborative group, Sande